News coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.1701265640673 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
PETX has been the subject of a number of analyst reports. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 21st. Credit Suisse Group reiterated an “outperform” rating and set a $8.00 price target (down previously from $9.00) on shares of Aratana Therapeutics in a research report on Friday, March 16th. Zacks Investment Research lowered Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, CL King upgraded Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Monday, March 12th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Aratana Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.68.
Shares of PETX traded down $0.15 during midday trading on Friday, reaching $4.98. The stock had a trading volume of 95,079 shares, compared to its average volume of 507,752. Aratana Therapeutics has a 52 week low of $3.67 and a 52 week high of $7.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.02 and a current ratio of 2.40. The company has a market capitalization of $228.35, a PE ratio of -5.16 and a beta of 2.91.
In other news, CEO Peter Steven St sold 19,367 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total value of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares of the company’s stock, valued at approximately $3,206,675.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Aratana Therapeutics (PETX) Share Price” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-share-price.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.